Aspira Pathlab & Diagnostics Ltd.
| BSE: 540788 | Sector: Health care |
| NSE: N.A. | ISIN Code: INE500C01017 |
| BSE 00:00 | 21 Jan | 95.00 |
-3.55 (-3.60%) |
OPEN
98.00 |
HIGH
98.30 |
LOW
93.75 |
| NSE 05:30 | 01 Jan | Aspira Pathlab & Diagnostics Ltd |
| OPEN | 98.00 |
| PREVIOUS CLOSE | 98.55 |
| VOLUME | 535 |
| 52-Week high | 124.15 |
| 52-Week low | 26.75 |
| P/E | 34.55 |
| Mkt Cap.(Rs cr) | 98 |
| Buy Price | 0.00 |
| Buy Qty | 0.00 |
| Sell Price | 0.00 |
| Sell Qty | 0.00 |
Aspira Pathlab & Diagnostics Ltd. (ASPIRAPATHLAB) - Net Profit
Net Profit
| COMPANY | LATEST(Rs) | CHG | CHG(%) | Net Profit (Rs crore) |
| Aurobindo Pharma | 655.20 | -6.40 | -0.97 | 3112.91 |
| Cipla | 866.90 | -15.80 | -1.79 | 2468.28 |
| Dr Reddy's Labs | 4498.50 | -94.70 | -2.06 | 2186.40 |
| Sun Pharma.Inds. | 809.05 | -10.60 | -1.29 | 2139.70 |
| Divi's Lab. | 4178.85 | -152.75 | -3.53 | 1954.72 |
| Alkem Lab | 3555.50 | 35.90 | 1.02 | 1685.08 |
| Glenmark Pharma. | 483.35 | -13.95 | -2.81 | 1649.45 |
| Cadila Health. | 410.05 | -8.55 | -2.04 | 1476.20 |
| Lupin | 903.45 | -35.75 | -3.81 | 1258.62 |
| Alembic Pharma | 773.30 | -8.60 | -1.10 | 1175.39 |
| Ipca Labs. | 1056.00 | -11.95 | -1.12 | 1140.77 |
| Torrent Pharma. | 3160.50 | -46.25 | -1.44 | 1137.85 |
| Gland Pharma | 3569.70 | -65.30 | -1.80 | 997.01 |
| Laurus Labs | 481.95 | -3.50 | -0.72 | 956.11 |
| Abbott India | 16987.05 | 146.50 | 0.87 | 690.69 |
| Ajanta Pharma | 2215.95 | 64.80 | 3.01 | 675.64 |
| Wockhardt | 409.75 | -8.45 | -2.02 | 593.29 |
| Granules India | 318.10 | -3.50 | -1.09 | 552.78 |
| Pfizer | 4744.45 | -6.55 | -0.14 | 497.61 |
| Sanofi India | 7328.80 | -99.80 | -1.34 | 477.60 |
Quick Links for Aspira Pathlab & Diagnostics:
-
News
Announcements Brokerage Reports Business Earnings Sector -
Corporate Action
AGM Board Meetings Bonus Dividends EGM Rights Split -
INFORMATION
Bulk Deals Company History MF Holding Listing Info Locations Shareholding -
Financials
Financial Overview Balance Sheet Profit & Loss Cash Flow Ratios Quarterly Results Half Yearly Results Nine Monthly Results Yearly Results -
Annual Report
Auditors Report Chairman's Speech Company Management Directors' Report Finished Goods Raw Materials -
Peer Comparison
Competition Market Cap Price Price Performance Net Sales Net Profit Total Assets Historical Prices
